What's Going On With Becton Dickinson Stock Wednesday?
FDA alerts Becton Dickinson customers to remove recalled Huons sodium chloride ampules from convenience kits. No injuries reported.
Read original at benzingaStocks · News reference
Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products
FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 6:00 PM
- Checked
- Aug 13, 2026, 6:00 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
FDA Issues Early Alert For High-Risk Issue With Becton Dickinson Convenience Kits; Becton Dickinson Advises Removal Of Recalled Components From Convenience Kits; Warns Against Use Of Sodium Chloride Ampules In Affected Bd Kits
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-becton-dickinson
Read original at benzingaRBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $190
RBC Capital analyst Kendall Au maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $180 to $190.
Read original at benzingaBTIG Reiterates Buy on Medline, Maintains $55 Price Target
BTIG analyst David Larsen reiterates Medline (NASDAQ:MDLN) with a Buy and maintains $55 price target.
Read original at benzingaReported Earlier, FDA Says Medline Issued Correction For Convenience Kits Containing B. Braun Bupivacaine Hydrochloride Components, Identified As Most Serious Recall Type; B. Braun Reported 35 Serious Injuries, No Deaths
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-recall-medline-issues-correction-convenience-kits-containing-b-braun-bupivacaine
Read original at benzingaJP Morgan Maintains Overweight on Medline, Lowers Price Target to $46
JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.
Read original at benzinga